Prostate cancer displays over-expression of a hormone receptor called androgen receptor. Traditional prostate cancer treatment includes hormone therapy, either by reducing androgen levels or blocking the receptor. This treatment is potent for a while; however, prostate cancer quickly develops resistance and becomes androgen-independent.<br/>This research proposes a potential strategy for treating prostate cancer involving the FDA-approved anti-alcoholism drug disulfiram in combination with copper metal. Particularly, this combinational treatment can reduce androgen receptor expression and induce apoptosis in prostate cancer cells that are resistant to current therapies. Analysis shows that these effects may be correlated with proteasome inhibition.

Effect of combination disulfiram-copper treatment on ARV-7 expression in castration-resistant prostate cancer

253rd National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.